Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.
Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.
Prenatal testing business Sequenom is the first company to buy the technology, which has applications in any setting in which genetic data needs mapping, sorting and deduplicating.
Calico, Google's semi-secretive biotech venture, stepped into the spotlight with a high-dollar collaboration this week, and now the California startup is mounting a big recruitment effort, according to a report.
In a desperate attempt to control the ongoing Ebola outbreak in West Africa, the World Health Organization is appealing to drug companies and international regulatory bodies to work together to get experimental therapies and vaccines out of the lab and into the clinic as soon as possible.
Facing dwindling sales and a thin late-stage pipeline, Merck KGaA is looking to accelerate its efforts in allergy drug development, signing a deal with an Austrian biotech with hopes of quickly seeding new programs in the field.
Endoscopic surgery isn't usually associated with diabetes, but Fractyl Laboratories yesterday announced encouraging clinical trial results for its endoscopic procedure to treat Type 2 diabetes and revealed a $40 million Series C financing round led by investment firm Mithril Capital Management.
OncoMed is moving on from tandem setbacks in its cancer pipeline now that the FDA has removed its final clinical hold on one of the biotech's oncology candidates, clearing it to resume enrollment in a Phase I study.
Edison Pharmaceuticals' in-development rare disease treatment missed its primary endpoint in a mid-stage trial, denting the company's plans for an expansive take on CNS R&D.
As cardiac devicemakers search for innovative ways to streamline products for patients, Swiss researchers have developed a self-powered pacemaker modeled after an automatic wristwatch that could provide an alternative to traditional pacing systems.